Please login to the form below

Not currently logged in
Email:
Password:

tivantinib

This page shows the latest tivantinib news and features for those working in and with pharma, biotech and healthcare.

Daiichi Sankyo to shut down German antibody unit U3

Daiichi Sankyo to shut down German antibody unit U3

Daiichi Sankyo is looking to new products such as novel oral anticoagulant (NOAC) Lixiana (edoxaban) - as well as pipeline candidates like tivantinib for liver cancer, quizartinib for leukaemia and mirogabalin for

Latest news

  • Daiichi Sankyo cuts a swathe through US workforce Daiichi Sankyo cuts a swathe through US workforce

    These include tivantinib for liver cancer - tipped by some analysts as a $600m product despite disappointing data in lung cancer - quizartinib for leukaemia and mirogabalin for fibromyalgia.

  • Roche drug fails in lung cancer trial Roche drug fails in lung cancer trial

    It remains to be seen whether the failed study has implications for other c-MET inhibitors in clinical trials, although the class has had other notable casualties, including ArQule's tivantinib

  • Daiichi, ArQule cancer drug tivantinib flunks another trial Daiichi, ArQule cancer drug tivantinib flunks another trial

    Daiichi, ArQule cancer drug tivantinib flunks another trial. Fails to meet endpoint in colorectal cancer study. ... to proceed with further clinical development of tivantinib in this tumour type ". 14th January 2013.

  • Daiichi and ArQule pull late-stage study of lung cancer drug

    Daiichi-Sankyo and ArQule have pulled a phase III trial investigating tivantinib (ARQ 197) in the treatment of non-small cell lung cancer (NSCLC). ... Fighting cancer is a complex process in that therapies work differently in different tumour settings,

  • Russian market for lung cancer drugs to hit $163m by 2015

    Kirin's tivantinib - should make their debut in or before 2015.". ... Meanwhile, Daiichi Sankyo began enrolling patients in Europe into a large, multinational phase III trial of tivantinib, its investigational small molecule inhibitor of the c-MET

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
McCann Health

The most globally awarded health agency network and currently Health Network agency of The Year. Comprising of two specialist agencies:...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics